Piotr Putaj
Director - Oligonucleotide Chemistry Vico Therpaeutics
Seminars
Friday 23rd January 2026
From Preclinical Evidence to Early Clinical Studies: Advancing VO659 for Huntington’s Disease
1:00 pm
- Development and clinical positioning of VO659, outlining the path from candidate selection through IND-enabling activities and entry into Phase 1/2a studies
- Translational strategies used to bridge preclinical pharmacology, safety, and target engagement with early clinical trial design in Huntington’s disease
- Broader implications of the VO659 program for advancing next-generation oligo therapies targeting CNS disorders
